ClinicalTrials.gg
CompletedNCT01979952Updated Apr 17, 2018Results posted

Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF)

A Phase 3 interventional study of Matching Placebo and Nintedanib in Idiopathic Pulmonary Fibrosis, sponsored by Boehringer Ingelheim. Completed at 25 sites in 3 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2018-04-17.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
113
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis — 1 open to participants now, 1 under way, none of them phase 3. nintedanib · Idiopathic Pulmonary Fibrosis.

Enrollment
4th of 16
113 · median 49
Started
2013
the only one that year
Phase 3
2 of 16
none open now
Registered
3rd of 16
by date
Lead sponsor
6 of 16
Boehringer Ingelheim

Among the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, this one is the 4th largest by enrollment, is the only one that started in 2013, is one of 2 in phase 3, and was the 3rd registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

1 of the 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis is open now. Recruiting first, the newest first:

About nintedanib

nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing nintedanib in Idiopathic Pulmonary Fibrosis, or all of them as a file.
02

Study summary

This is an 6 month multi-centre, prospective, randomized, placebo controlled, double blind clinical trial followed by conversion of each arm to active nintedanib for an additional 6 months comparing the effect of nintedanib 150mg bis in die (BID twice daily) on the progression of IPF measured by using High Resolution Computerized Tomography(HRCT), lung function, functional component (6MWT), biomarkers, and PRO component (PROs) with continued treatment and assessments for up to 18 months.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written consistent with International Conference on Harmonisation Good Clinical Practice (ICH-GCP) and local laws signed prior to entry into the study
  2. Patient aged >= 40 years at Visit 1.
  3. IPF diagnosed, according to the 2011 American Thoracic Society (ATS) / European Respiratory Society (ERS) / Japanese Respiratory Society(JRS)/ Latin American Thoracic Association (ALAT)/ Latin American Thoracic Association/ Idiopathic Pulmonary Fibrosis (IPF) guidelines for diagnosis and management, within 5 years and reaffirmed applying 2011 Guidelines (P11-07084) if diagnosed >2 years and up to 5 year from Visit 1,. Diagnosis must be confirmed by chest High Resolution Computerized Tomography (HRCT) taken within 24 months of Visit 1. All HRCT results reported to be possible or inconsistent usual interstitial pneumonia (UIP) must have confirmatory pathology.
  4. Carbon monoxide Diffusing capacity or Transfer factor of the lung for carbon monoxide (DLCO) (corrected for ): 30%-79% predicted of normal
  5. Forced Vital Capacity (FVC) >= 50% predicted of normal at Visit 1 and Visit 2

Exclusion criteria

Exclusion criteria:

  1. , ALT > 1.5 fold
  2. > 1.5 fold ULN
  3. Bleeding risk:

    1. Patients who require fibrinolysis, full-dose therapeutic anticoagulation (e.g. vitamin K antagonists, dabigatran, heparin, hirudin), or high dose antiplatelet therapy. Exceptions: prophylactic low dose heparin or heparin flush as needed for maintenance of an indwelling intravenous device (e.g. enoxaparin 4000 IU s.c. per day) and prophylactic use of antiplatelet therapy (e.g. acetyl salicylic acid up to 325 mg/d, or clopidogrel at 75 mg/d, or equivalent doses of other antiplatelet therapy)
    2. History of hemorrhagic Central Nervous System (CNS) event within 12 months
    3. Any of the following within 3 months:

      • Haemoptysis or haematuria.
      • Active gastro-intestinal bleeding or ulcers.
      • Major injury or surgery.
    4. Coagulation parameters: (INR) > 2, prothrombin time (PT) and partial thromboplastin time (PTT) > 150% of institutional ULN.
  4. Planned major surgery within the next 3 months, including lung transplantation, major abdominal or major intestinal surgery.
  5. Thrombotic risk

    1. Known inherited predisposition to thrombosis.
    2. History of thrombotic event (including stroke and ) within 12 months
  6. Current or planned usage of any drug during the course of this trial
  7. Previous treatment with nintedanib within a clinical trial in the previous 3 months and discontinuation of nintedanib study treatment due to an adverse event
  8. Known to the trial drug or its component
  9. A disease or condition which in the opinion of investigator may put the patient at risk because of participation in this trial or limit the patient's ability to participate in this trial. Patients will be excluded if they require greater than 12L/min oxygen, are not ambulatory or require use of a walker or cane during the 6 Minute Titration Walk Test. Patients who cannot complete the 6 Minute Titration Walk Test are excluded from participation.
  10. Alcohol or drug abuse which in the opinion of the investigator would interfere with trial participation.
  11. Pregnant women or women who are breast feeding or of child bearing potential not using two effective methods of (one barrier and one highly effective non-barrier) for at least 1 month prior to trial and/or not committing to using it until 3 months after end of treatment.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
113 participants (actual)

Study arms

  • Experimental
    Nintedanib

    150 mg twice daily

    Drug: Nintedanib

  • Placebo comparator
    Placebo

    twice daily dosing

    Drug: Matching Placebo

Interventions

  • DrugMatching Placebo

    twice daily dosing

  • gelating capsule

06

What researchers measure

Primary outcomes

  1. Relative Change From Baseline in High Resolution Computerized Tomography (HRCT) Quantitative Lung Fibrosis (QLF) Score at 6 Months

    Relative change from baseline in HRCT QLF score at 6 months was calculated as the difference of the QLF score at month 6 minus the QLF score at baseline divided by the baseline QLF score. The QLF score itself ranges from 0 to 100%, where greater values represent a greater amount of lung fibrosis and are considered a worse health status. Hence smaller relative changes from baseline (i.e., ratios) were considered favorable. HCRT assessment obtained during screening visit was considered as baseline.

    Time frame: Baseline and 6 Months

Secondary outcomes

  1. Effect of Six Month Delayed Treatment Onset: Relative Change From Baseline in HRCT QLF Score at 12 Months

    Relative change from baseline in HRCT QLF score at 12 months was calculated as the ratio of the QLF score at 12 months to baseline. Greater values of the QLF score represented a worse health status and hence smaller relative changes from baseline (i.e., ratios) were considered favorable. HCRT assessment obtained during screening visit was considered as baseline. Note that due to the change in study design, patients randomized to the placebo group were treated with nintedanib after completion of the first 6-month treatment period. Therefore, this new endpoint was defined to address the effect of a 6-month delayed onset of nintedanib treatment.

    Time frame: Baseline and 12 Months

  2. Absolute Change in Forced Vital Capacity (FVC) From Baseline at 6 Months

    Absolute change in Forced Vital Capacity (FVC) from baseline at 6 months is presented.

    Time frame: Baseline and 6 Months

  3. Relative Change in FVC From Baseline at 6 Months

    Relative change in FVC from baseline at 6 months is presented.

    Time frame: Baseline and 6 Months

  4. Categorical Change in FVC From Baseline at 6 Months

    Percentage of participants reporting categorical change in FVC from baseline at 6 months are presented.

    Time frame: Baseline and 6 Months

  5. St. George's Respiratory Questionnaire (SGRQ) Total Score Change From Baseline at 6 Months

    SGRQ total score change from baseline at 6 months is presented. SGRQ is a health-related quality of life questionnaire divided into 3 components : symptoms, activity and impact. The total score (summed weights) can range from 0 to 100 with a lower score denoting a better health status. Means provided are the adjusted means based on all analyzed patients in the model (not only patients with a baseline and measurement at month 6).

    Time frame: Baseline and 6 Months

  6. 6MWT Total Distance Walked Change From Baseline at 6 Months

    Change in total distance covered in 6-minute walk test (6MWT) from baseline at 6 month is presented. The 6-Minutes Walk Test (6-MWT) was conducted according to the American Thoracic Society (ATS) Criteria.

    Time frame: Baseline and 6 Months

  7. University of California San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) Change From Baseline at 6 Months

    University of California San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) change from baseline at 6 months is presented. Shortness of Breath Questionnaire measures the shortness of breath. It comprises of 24 items. Each item is scored on a scale between 0-5 where 5 represents maximal breathlessness. The responses to all items are summed up to provide the overall score that can range from 0 (best outcome) to 120 (worst outcome). Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at month 6).

    Time frame: Baseline and 6 Months

  8. All-cause Mortality at 6 Months

    Percentage of subjects died from all causes between 0 to 6 months are presented.

    Time frame: 6 Months

  9. Respiratory Hospitalizations at 6 Months

    Percentage of subjects hospitalized due to respiratory problems between 0 to 6 months are presented.

    Time frame: 6 Months

  10. Respiratory Mortality at 6 Months

    Percentage of subjects who died due to respiratory cause between 0 to 6 months are presented.

    Time frame: 6 Months

  11. Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbations at 6 Months

    Percentage of subjects experienced first acute IPF exacerbations (based on Investigator reported adverse events) between 0 to 6 months are presented.

    Time frame: 6 Months

07

Results

Posted Apr 17, 2018
Limitations and caveats
This study was an exploratory trial that was not statistically powered to demonstrate significant differences between treatment groups for the efficacy endpoints evaluated.

Participant flow

Patients were randomized to receive nintedanib or placebo in 1:1 ratio. After Global Amendment 1, study design was changed to exploratory, and duration of double blind, placebo-controlled part of study was reduced from 12 months to 6 months, followed by conversion of all patients to open-label nintedanib treatment for a duration of up to 18 months.

Participant flow — Overall Study
MilestoneNintedanibPlacebo
Started5657
Completed4851
Not completed86
Withdrew: Adverse event45
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject21
Withdrew: Other than specified above10

Outcome measures

PrimaryRelative Change From Baseline in High Resolution Computerized Tomography (HRCT) Quantitative Lung Fibrosis (QLF) Score at 6 Months

Relative change from baseline in HRCT QLF score at 6 months was calculated as the difference of the QLF score at month 6 minus the QLF score at baseline divided by the baseline QLF score. The QLF score itself ranges from 0 to 100%, where greater values represent a greater amount of lung fibrosis and are considered a worse health status. Hence smaller relative changes from baseline (i.e., ratios) were considered favorable. HCRT assessment obtained during screening visit was considered as baseline.

Time frame:
Baseline and 6 Months
Reported as:
Least squares mean · percent change
Relative Change From Baseline in High Resolution Computerized Tomography (HRCT) Quantitative Lung Fibrosis (QLF) Score at 6 Months
percent changeNintedanibPlacebo
Relative Change From Baseline in High Resolution Computerized Tomography (HRCT) Quantitative Lung Fibrosis (QLF) Score at 6 Months11.407 ± 4.481914.583 ± 4.3297
Statistical analysis
  • Nintedanib vs Placebo · ANCOVA · Adjusted mean difference: 3.176 · 95% CI -9.227 to 15.579As per the Clinical Trial Protocol, this is an exploratory trial hence p-values were not calculated.
SecondaryEffect of Six Month Delayed Treatment Onset: Relative Change From Baseline in HRCT QLF Score at 12 Months

Relative change from baseline in HRCT QLF score at 12 months was calculated as the ratio of the QLF score at 12 months to baseline. Greater values of the QLF score represented a worse health status and hence smaller relative changes from baseline (i.e., ratios) were considered favorable. HCRT assessment obtained during screening visit was considered as baseline. Note that due to the change in study design, patients randomized to the placebo group were treated with nintedanib after completion of the first 6-month treatment period. Therefore, this new endpoint was defined to address the effect of a 6-month delayed onset of nintedanib treatment.

Time frame:
Baseline and 12 Months
Reported as:
Least squares mean · percent change
Effect of Six Month Delayed Treatment Onset: Relative Change From Baseline in HRCT QLF Score at 12 Months
percent changeNintedanibPlacebo
Effect of Six Month Delayed Treatment Onset: Relative Change From Baseline in HRCT QLF Score at 12 Months13.103 ± 4.545415.622 ± 4.4714
Statistical analysis
  • Nintedanib vs Placebo · ANCOVA · Adjusted mean difference: 2.519 · 95% CI -10.258 to 15.296As per the Clinical Trial Protocol, this is an exploratory trial hence p-values were not calculated
SecondaryAbsolute Change in Forced Vital Capacity (FVC) From Baseline at 6 Months

Absolute change in Forced Vital Capacity (FVC) from baseline at 6 months is presented.

Time frame:
Baseline and 6 Months
Reported as:
Least squares mean · milliliter (mL)
Absolute Change in Forced Vital Capacity (FVC) From Baseline at 6 Months
milliliter (mL)NintedanibPlacebo
Absolute Change in Forced Vital Capacity (FVC) From Baseline at 6 Months-14.18 ± 31.050-83.18 ± 28.067
Statistical analysis
  • Nintedanib vs Placebo · Mixed Models Analysis · Adjusted mean difference: 69.00 · 95% CI -8.74 to 146.75As per the Clinical Trial Protocol, this is an exploratory trial hence p-values were not calculated.
SecondaryRelative Change in FVC From Baseline at 6 Months

Relative change in FVC from baseline at 6 months is presented.

Time frame:
Baseline and 6 Months
Reported as:
Least squares mean · percentage of change
Relative Change in FVC From Baseline at 6 Months
percentage of changeNintedanibPlacebo
Relative Change in FVC From Baseline at 6 Months-0.67 ± 1.05-3.02 ± 0.95
Statistical analysis
  • Nintedanib vs Placebo · Mixed Models Analysis · Adjusted mean difference: 2.36 · 95% CI -0.29 to 5.00As per the Clinical Trial Protocol, this is an exploratory trial hence p-values were not calculated.
SecondaryCategorical Change in FVC From Baseline at 6 Months

Percentage of participants reporting categorical change in FVC from baseline at 6 months are presented.

Time frame:
Baseline and 6 Months
Reported as:
Number · Percentage of participants
Categorical Change in FVC From Baseline at 6 Months
Percentage of participantsNintedanibPlacebo
Decrease >10% or 200 mL6.523.9
Change within ≤10% AND ≤200 mL76.171.7
Increase >10% or 200 mL17.44.3
SecondarySt. George's Respiratory Questionnaire (SGRQ) Total Score Change From Baseline at 6 Months

SGRQ total score change from baseline at 6 months is presented. SGRQ is a health-related quality of life questionnaire divided into 3 components : symptoms, activity and impact. The total score (summed weights) can range from 0 to 100 with a lower score denoting a better health status. Means provided are the adjusted means based on all analyzed patients in the model (not only patients with a baseline and measurement at month 6).

Time frame:
Baseline and 6 Months
Reported as:
Least squares mean · Units on a scale
St. George's Respiratory Questionnaire (SGRQ) Total Score Change From Baseline at 6 Months
Units on a scaleNintedanibPlacebo
St. George's Respiratory Questionnaire (SGRQ) Total Score Change From Baseline at 6 Months-2.24 ± 1.682-2.19 ± 1.699
Statistical analysis
  • Nintedanib vs Placebo · Mixed Models Analysis · Adjusted mean difference: -0.05 · 95% CI -4.89 to 4.79
Secondary6MWT Total Distance Walked Change From Baseline at 6 Months

Change in total distance covered in 6-minute walk test (6MWT) from baseline at 6 month is presented. The 6-Minutes Walk Test (6-MWT) was conducted according to the American Thoracic Society (ATS) Criteria.

Time frame:
Baseline and 6 Months
Reported as:
Least squares mean · meters
6MWT Total Distance Walked Change From Baseline at 6 Months
metersNintedanibPlacebo
6MWT Total Distance Walked Change From Baseline at 6 Months4.93 ± 11.415-13.00 ± 11.476
Statistical analysis
  • Nintedanib vs Placebo · Mixed Models Analysis · Adjusted mean difference: 17.94 · 95% CI -14.21 to 50.09
SecondaryUniversity of California San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) Change From Baseline at 6 Months

University of California San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) change from baseline at 6 months is presented. Shortness of Breath Questionnaire measures the shortness of breath. It comprises of 24 items. Each item is scored on a scale between 0-5 where 5 represents maximal breathlessness. The responses to all items are summed up to provide the overall score that can range from 0 (best outcome) to 120 (worst outcome). Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at month 6).

Time frame:
Baseline and 6 Months
Reported as:
Least squares mean · Units on a scale
University of California San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) Change From Baseline at 6 Months
Units on a scaleNintedanibPlacebo
University of California San Diego Shortness of Breath Questionnaire (UCSD-SOBQ) Change From Baseline at 6 Months3.42 ± 2.156-1.46 ± 2.192
Statistical analysis
  • Nintedanib vs Placebo · Mixed Models Analysis · Adjusted mean difference: 4.89 · 95% CI -1.47 to 11.25
SecondaryAll-cause Mortality at 6 Months

Percentage of subjects died from all causes between 0 to 6 months are presented.

Time frame:
6 Months
Reported as:
Number · Percentage of participants
All-cause Mortality at 6 Months
Percentage of participantsNintedanibPlacebo
All-cause Mortality at 6 Months0.05.3
SecondaryRespiratory Hospitalizations at 6 Months

Percentage of subjects hospitalized due to respiratory problems between 0 to 6 months are presented.

Time frame:
6 Months
Reported as:
Number · Percentage of participants
Respiratory Hospitalizations at 6 Months
Percentage of participantsNintedanibPlacebo
Respiratory Hospitalizations at 6 Months0.07.0
SecondaryRespiratory Mortality at 6 Months

Percentage of subjects who died due to respiratory cause between 0 to 6 months are presented.

Time frame:
6 Months
Reported as:
Number · Percentage of participants
Respiratory Mortality at 6 Months
Percentage of participantsNintedanibPlacebo
Respiratory Mortality at 6 Months0.03.5
SecondaryAcute Idiopathic Pulmonary Fibrosis (IPF) Exacerbations at 6 Months

Percentage of subjects experienced first acute IPF exacerbations (based on Investigator reported adverse events) between 0 to 6 months are presented.

Time frame:
6 Months
Reported as:
Number · Percentage of participants
Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbations at 6 Months
Percentage of participantsNintedanibPlacebo
Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbations at 6 Months1.81.8

Adverse events

Collected over From first drug administration till 28 days after end of treatment; up to 19 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nintedanib—11/56 (19.6%)54/56 (96.4%)
Placebo—14/57 (24.6%)51/57 (89.5%)
Most frequent serious events
Showing 10 of 40
Most frequent serious events
EventNintedanibPlacebo
Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders1/563/57
Respiratory failureRespiratory, thoracic and mediastinal disorders2/561/57
PneumoniaInfections and infestations0/562/57
Cardiogenic shockCardiac disorders1/560/57
Myocardial infarctionCardiac disorders1/560/57
Intestinal infarctionGastrointestinal disorders1/560/57
Clostridium difficile infectionInfections and infestations1/560/57
InfluenzaInfections and infestations1/560/57
Lyme diseaseInfections and infestations1/560/57
SepsisInfections and infestations1/560/57
Most frequent other events
Showing 10 of 44
Most frequent other events
EventNintedanibPlacebo
DiarrhoeaGastrointestinal disorders43/5640/57
NauseaGastrointestinal disorders16/5620/57
CoughRespiratory, thoracic and mediastinal disorders9/5615/57
Weight decreasedInvestigations13/564/57
Decreased appetiteMetabolism and nutrition disorders12/566/57
FatigueGeneral disorders11/569/57
VomitingGastrointestinal disorders10/569/57
NasopharyngitisInfections and infestations5/569/57
HeadacheNervous system disorders7/569/57
DyspnoeaRespiratory, thoracic and mediastinal disorders8/569/57

Baseline characteristics

Treated Set (TS) consisted of patients who were randomized to a treatment group and received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(Years)NintedanibPlaceboTotal
Mean68.8 ± 7.666.2 ± 9.467.5 ± 8.6
Sex: Female, Male
Sex: Female, Male(Participants)NintedanibPlaceboTotal
Female112031
Male453782
08

Study locations

25 sites
  • Western CT Medical Group, P.C.
    Danbury, Connecticut 06810, United States
  • Clinical Research Center Sarasota Memorial Hosptial
    Sarasota, Florida 34239, United States
  • Chest Medicine Clinical Services
    Skokie, Illinois 60076, United States
  • Baptist Health Lexington
    Lexington, Kentucky 40503, United States
  • Minnesota Lung Research
    Minneapolis, Minnesota 55407, United States
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Winthrop University Hospital
    Mineola, New York 11501, United States
  • ID Clinical Research, LTD
    Toledo, Ohio 43608, United States
  • The Oregon Clinic
    Portland, Oregon 97220, United States
  • Lowcountry Lung and Crit Care
    Charleston, South Carolina 29406, United States
  • Annette C & Harold C Simmons Transplant Institute
    Dallas, Texas 75246, United States
  • University of Alberta Hospital (University of Alberta)
    Edmonton, Alberta T6G 2G3, Canada
  • Vancouver General Hospital
    Vancouver, British Columbia V5Z 1M9, Canada
  • St. Paul's Hospital
    Vancouver, British Columbia V6Z 1Y6, Canada
  • Concordia Hospital
    Winnipeg, Manitoba R2K 3S8, Canada
  • QEII Health Sciences Centre (Dalhousie University)
    Halifax, Nova Scotia B3H 3A7, Canada
  • St. Joseph's Healthcare Hamilton
    Hamilton, Ontario L8N 4A6, Canada
  • CHUS Fleurimont
    Sherbrooke, Quebec J1H 5N4, Canada
  • Cukurova Universitesi Tip Fakultesi Gog. Hast. Anabilim Dali
    Adana, 01330, Turkey
  • Ankara Universitesi Tip Fakultesi
    Ankara, 06100, Turkey
  • Istanbul Universitesi Cerrahpasa Tip Fakultesi
    Istanbul, 34098, Turkey
  • Yedikule Gog. Hst. EAH
    Istanbul, 34760, Turkey
  • Sureyyapasa Gogus Hast. ve Gogus Cer. Egit. ve Aras. Has.
    Istanbul, 34844, Turkey
  • Ege Universitesi T.F.
    Izmir, 35100, Turkey
  • Dr.Suat Seren EAH
    Izmir, 35110, Turkey
09

References and documents

Publications

  • Glaspole I, Bonella F, Bargagli E, Glassberg MK, Caro F, Stansen W, Quaresma M, Orsatti L, Bendstrup E. Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities. Respir Res. 2021 Apr 26;22(1):125. doi: 10.1186/s12931-021-01695-y. PubMed 33902584 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2013 to primary completion in Oct 2016, 35 months.

Results were first posted in Apr 2018, 1 year 5 months after primary completion. A results delay was requested in Jun 2017.

Of 24 phase 3 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 60. This study's 35 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2013
First posted
Nov 8, 2013
StartActual
Nov 26, 2013
Primary completionActual
Oct 27, 2016
CompletionActual
Oct 27, 2016
Results delay requested
Jun 7, 2017
Results first posted
Apr 17, 2018
Last update
Apr 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01979952
Responsible party
Sponsor
First posted
Nov 8, 2013
Start date
Nov 26, 2013
Primary completion
Oct 27, 2016
Completion
Oct 27, 2016
Results posted
Apr 17, 2018
Last update
Apr 17, 2018

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nintedanib

Start the discussion